Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2Phase 1/2 1

Status

Completed 3

Sponsor Class

OTHER_GOV 1OTHER 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 10Thoracic 4Lymphoid 3Genitourinary 3Dermatologic 3Other hematologic neoplasm 2Gastrointestinal 2NET 1Myeloid 1Endocrine 1Classical hematology 1

Conditions

Melanoma 2Uveal Melanoma 1

Interventions

Nivolumab 114Ipilimumab 114pembrolizumab 108aldesleukin 76Cyclophosphamide 70fludarabine phosphate 51Interleukin-2 48Temozolomide 41Dacarbazine 36trametinib 33dabrafenib 30Bevacizumab 30sargramostim 29Radiotherapy 29incomplete Freund's adjuvant 27fludarabine 27Vemurafenib 25Radiosurgery 25Carboplatin 25Paclitaxel 23binimetinib 22Biopsy 22CTLA-4 Antigen 21Peripheral Blood Stem Cell Transplantation 20encorafenib 19cemiplimab 19atezolizumab 19HhAntag691 19Mycophenolic Acid 18Aminolevulinic Acid 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × entinostat × Dermatologic × Clear all
NCT03765229 2024-01-10

An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma

UNC Lineberger Comprehensive Cancer Center

Phase 2 Completed
11 enrolled 12 charts
Dermatologic

Melanoma

NCT02697630 2023-12-08

PEMDAC

Vastra Gotaland Region

Phase 2 Completed
29 enrolled
Dermatologic

Uveal Melanoma

NCT00185302 2015-12-14

Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma

Bayer

Phase 2 Completed
28 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡